Table 1 Baseline characteristics of the study cohort

Sex

Male

32 (17.0)

156 (83.0)

188 (64.2)

Female

14 (13.6)

89 (86.4)

103 (35.2)

NR

1 (50.0)

1(50.0)

2 (0.7)

Age (In years), at Month0

Mean, SD

34.6, 7.5

36.6, 8.5

36.7, 8.6

15–34

23 (18.1)

104 (81.9)

127 (43.5)

35–44

16 (13.3)

104 (86.7)

120 (41.1)

> = 45

6 (13.3)

39 (86.7)

45 (15.4)

Original First Line Regimen

D4T/3TC/NVP

15 (13.0)

100 (87.0)

115 (39.2)

D4T/3TC/EFV

59 (78.7)

16 (21.3)

75 (25.6)

AZT/3TC/NVP

32 (78.0)

9 (22.0)

41 (14.0)

AZT/3TC/EFV

54 (91.5)

5 (8.5)

59 (20.1)

TDF/3TC/EFV

2 (66.7)

1 (33.3)

3 (1.0)

Original Regimen substituted

Yes

34 (16.8)

168 (83.2)

202 (68.9)

No

79 (87.8)

11 (12.2)

90 (30.7)

NR

0

1

1 (0.3)

Switch to second line regimen

Yes

2 (33.3)

4 (66.7)

6 (2.0)

No

44 (15.3)

243 (84.7)

287 (98.0)

Baseline CD4 count, cells/mm³

Median, IQR

122 (67–190)

114 (63–176)

115 (64–176)

0–49

6 (12.8)

41 (87.2)

47 (16.2)

50–99

12 (16.0)

63 (84.0)

75 (25.9)

100–149

9 (14.3)

54 (85.7)

63 (21.7)

150–199

8 (12.9)

54 (87.1)

62 (21.4)

> = 200

10 (23.3)

33 (76.7)

43 (14.8)

Base line functional status

Work

29 (15.9)

153 (84.1)

182 (62.1)

Ambulatory

9 (15.5)

49 (84.5)

58 (19.8)

Bedridden

3 (12.0)

22 (88.0)

25 (8.5)

NR

5 (17.9)

23 (82.1)

28 (9.6)

Body Mass Index. Kg/m2

<18.5

12 (18.8)

52 (81.2)

64 (21.8)

> = 18.5

15 (13.9)

93 (86.1)

108 (36.9)

NR

19 (15.7)

102 (84.3)

121 (41.3)

Gap between testing and treatment initiation

Same month

29 (17.0)

142 (83.0)

171 (59.0)

1–24 months

13 (13.4)

84 (86.6)

97 (33.4)

>24 months

4 (18.2)

18 (81.8)

22 (7.6)

Adherence

Good

35 (15.2)

195 (84.8)

230 (78.5)

Fair/ poor

10 (18.5)

44 (81.5)

54 (18.4)

NR

1 (11.1)

8 (88.9)

9 (3.1)